European Medicines Agency Accepts Application Seeking New Indication For Prevenar 13 For Prevention Of Pneumococcal Pneumonia In Adults

August 7th, 2014 -Application Includes Data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency (EMA) has accepted Pfizer’s application seeking to expand the indication for Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes contained in …

Pfizer Presents Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults Evaluating Efficacy Of Prevenar 13*

Study Findings, Presented at ISPPD, Demonstrate that Prevenar 13 Can Prevent Vaccine-Type Community-Acquired Pneumonia March 12, 2014 Pfizer Inc. today presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) prevented a first episode of vaccine-type community-acquired pneumonia (CAP) in adults 65 …